Kailera Therapeutics, Inc. (KLRA) Stock Statistics & Valuation Metrics

Kailera Therapeutics, Inc. has a market cap or net worth of $2.85B. The enterprise value is $0.00.

Kailera Therapeutics, Inc. has 129,565,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kailera Therapeutics, Inc.’s return on equity (ROE) is 0.42 and return on invested capital (ROIC) is -24.48%.

The current PE Ratio of Kailera Therapeutics, Inc. is ―. Kailera Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, Kailera Therapeutics, Inc. had revenue of 0.00 and earned -148.96M in profits. Earnings per share was -1.26.

In the last 12 months, operating cash flow was -68.31M and capital expenditures 0.00, giving a free cash flow of -68.31M billion.

Kailera Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Kailera Therapeutics, Inc. upcoming earnings date is May 26, 2026, After Close (Confirmed).

Kailera Therapeutics, Inc. as a current ratio of 12.01, with Debt / Equity ratio of -3.02%

In the past 12 months, Kailera Therapeutics, Inc. has paid 0.00 in taxes.

Kailera Therapeutics, Inc. EV to EBITDA ratio is -18.46, with an EV/FCF ratio of -23.85.

Kailera Therapeutics, Inc. has $519.17M in cash and marketable securities with $10.47M in debt, giving a net cash position of $508.70M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Kailera Therapeutics, Inc. is $39.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy